Moreover, while the application of PCSK9 inhibitors in ischemic stroke primarily pertains to the chronic phase, Alirocumab and Evolocumab have shown the capability to rapidly reduce PCSK9 levels within hours, potentially diminishing the associated risk of ischemic stroke. This evidence concerns the gene PCSK9 and ischemic stroke.